总时间（秒）：812.51
问答时间（秒）：807.58

```json
[
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "Wildtype",
                "alt": "",
                "position": ""
            },
            "variant_string_id": "a-Syn WT"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether both wild-type and mutant a-Syn proteins were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the Materials and Methods or Results sections."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the wild-type a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the Materials and Methods or Results sections."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the Materials and Methods or Results sections."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A53T",
                "position": ""
            },
            "variant_string_id": "a-Syn A53T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A53T) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A53T variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "D57N",
                "position": ""
            },
            "variant_string_id": "a-Syn D57N"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including D57N) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the D57N variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A53E",
                "position": ""
            },
            "variant_string_id": "a-Syn A53E"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A53E) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A53E variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A53T",
                "position": ""
            },
            "variant_string_id": "a-Syn A53T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A53T) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A53T variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A53E",
                "position": ""
            },
            "variant_string_id": "a-Syn A53E"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A53E) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A53E variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A53V",
                "position": ""
            },
            "variant_string_id": "a-Syn A53V"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A53V) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A53V variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A53E",
                "position": ""
            },
            "variant_string_id": "a-Syn A53E"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A53E) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A53E variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A53T",
                "position": ""
            },
            "variant_string_id": "a-Syn A53T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A53T) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A53T variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P/E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K/A53T",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P/E46K/A53T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K/A53T) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K/A53T variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K/A53T/A50G",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P/E46K/A53T/A50G"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K/A53T/A50G) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K/A53T/A50G variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A50G/G93C",
                "position": ""
            },
            "variant_string_id": "a-Syn A50G/G93C"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A50G/G93C) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A50G/G93C variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A50G/A53T",
                "position": ""
            },
            "variant_string_id": "a-Syn A50G/A53T"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A50G/A53T) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A50G/A53T variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A53T/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A53T_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A53T/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A53T/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c. Variant Controls",
                        "questions": [
                            {
                                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls? OR Were known benign variants used as controls? OR Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria without relying on PS3/BS3 evidence themselves?",
                                "answer": "No information regarding the use of variant controls is provided in the paper."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            },
            {
                "step_name": "Step 4: Apply evidence to individual variant interpretation",
                "sub_steps": [
                    {
                        "sub_step_name": "4a. Statistical Analyses",
                        "questions": [
                            {
                                "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                                "answer": "No information regarding statistical analyses or OddsPath calculations is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 4b."
                    },
                    {
                        "sub_step_name": "4b. No OddsPath Calculation",
                        "questions": [
                            {
                                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                                "answer": "The paper does not provide information about the number of variant controls used."
                            }
                        ],
                        "internal_decision": "Max PS3_supporting / Max BS3_supporting"
                    }
                ]
            }
        ],
        "overall_conclusion": "The paper does not provide sufficient functional evidence to classify the A30P/E46K variant of a-Syn as pathogenic or benign."
    },
    {
        "variant_id": {
            "Gene": "a-Syn",
            "Protein_Change": {
                "ref": "",
                "alt": "A30P/E46K",
                "position": ""
            },
            "variant_string_id": "a-Syn A30P_E46K"
        },
        "functional_evidence_aim": "Pathogenic",
        "assessment_steps": [
            {
                "step_name": "Step 1: Define the disease mechanism",
                "extracted_paper_info": "The paper discusses that a-Syn, when exposed to certain conditions (mutations, protein overexpression, exposure to death-inducing stimuli, alterations in post-translational modifications, impairment of the ubiquitin-proteasome pathway of protein degradation, or cell phenotype) can contribute to disease pathogenesis.",
                "internal_judgment": "YES"
            },
            {
                "step_name": "Step 2: Evaluate applicability of general classes of assays used in the field",
                "extracted_paper_info": "",
                "internal_judgment": "The paper does not explicitly mention the specific class of functional assay used for a-Syn, but it is implied that they are evaluating its impact on cell phenotype (cell viability, apoptosis, etc.), which is a common approach in studying protein function and disease pathogenesis.",
                "internal_decision": "YES"
            },
            {
                "step_name": "Step 3: Evaluate validity of specific instances of assays",
                "sub_steps": [
                    {
                        "sub_step_name": "3a. Basic Controls and Replicates",
                        "questions": [
                            {
                                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                                "answer": "It is not explicitly mentioned whether wild-type and mutant a-Syn proteins (including A30P/E46K) were used as controls in the study."
                            },
                            {
                                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                                "answer": "No information regarding experimental repetition is provided in the paper."
                            }
                        ],
                        "internal_decision": "Proceed to Sub-step 3b."
                    },
                    {
                        "sub_step_name": "3b. Accepted/Validated Assay",
                        "questions": [
                            {
                                "question": "Has the specific instance of the assay been: a) Broadly accepted historically (e.g., standard technique in the field)? OR b) Previously validated in other studies (cited)? OR c) Provided as a commercial kit with defined performance metrics, but where controls/replicates are not documented for the specific instance of the assay in this paper?",
                                "answer": "It is unclear whether the specific assays used in the study are broadly accepted historically or previously validated in other studies. There is no mention of using a commercial kit."
                            }
                        ],
                        "internal_decision": "Do not use PS3/BS3"
                    },
                    {
                        "sub_step_name": "3c